Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin and Rituximab as First-Line Treatment in Indolent Non-Hodgkin's Lymphoma
NCT00110149Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2004
- Primary completion
- May 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in Non-Hodgkin lymphoma (NHL), sponsored by Beth Israel Deaconess Medical Center. Started May 2004; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00110149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110149.